Additionally, Pan et al. had found that Bcl-2 inhibition and p53 activation could overcome apoptosis resistance and induce synthetic lethality in AML models.441 In phase II clinical trial, the safety and early efficacy of idasanutlin in combination with ABT-199 in young patients with neuroblastoma, AML, and ALL were evaluated (NCT04029688). The gene discussed is BCL2; the disease is acute myeloid leukemia.